Worldwide Biotech/Biopharma Alliance (From Nov. 12 to Otc. 30, 2012)
On Nov. 12, 2012, Caris Life Sciences Enhances Molecular Profiling Service With Addition of ROS1 and MGMT-Methylation Biomarkers. These markers are believed to serve as clinically-important aids in the development of treatment plans for patients with non-small cell lung cancer (NSCLC) and glioblastoma.
On Nov. 8, 2012, Australian infectious disease therapy development company BioDiem Ltd signed an agreement with Griffith University to expand the range of variants of BioDiem’s broad spectrum antimicrobial compound, BDM-I.
On Nov. 7, 2012, MorphoSys AG announced an expansion of its strategic antibody alliance with Novartis. The collaboration is to benefit from access to newest technologies.
On Nov. 6, 2012, Zhongyuan Union Stem Cell Bioengineering Co. has signed a memorandum of understanding to set up a stem cell JV with Cell Therapy Ltd. of Wales. The JV, which will have $8 million in startup capital, will use stromal (connective tissue) cells from the germinal layer to treat heart failure.
On Oct. 30, 2012, TPP Global Development Ltd (TPP) entered into collaboration with Sprint Bioscience AB to develop small molecule inhibitors of choline kinase as human therapeutics for the treatment of cancer.
Tags: Cooperation, Alliance, Molecular Profiling Service, Broad Spectrum Antimicrobial Compound, Antibody, Stem Cell, Small Molecule Inhibitor